MustGrow Biologics (TSE:MGRO)
:MGRO
Want to see TSE:MGRO full AI Analyst Report?
MGRO Stock Chart & Stats
C$0.49
C$0.01(0.67%)
At close: 4:00 PM EST
C$0.49
C$0.01(0.67%)
Day’s Range― - ―
52-Week RangeC$0.49 - C$0.99
Previous CloseN/A
Volume4.97K
Average Volume (3M)27.52K
Market Cap
C$33.55M
Enterprise ValueC$33.21M
Total Cash (Recent Filing)C$918.77K
Total Debt (Recent Filing)C$584.13K
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding58,854,360
10 Day Avg. Volume43,344
30 Day Avg. Volume27,516
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)39.49
Price to Sales (P/S)4.13
P/FCF Ratio-5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)C$25.00M
Bulls Say, Bears Say
Bulls Say
Strong TTM Revenue GrowthA nearly tenfold rise in TTM revenue demonstrates successful early commercialization and meaningful customer adoption of MustGrow's biologic products. If sustained, this growth can expand scale, enable margin improvement through operating leverage, and validate the product-market fit needed for longer-term profitability.
Specialized Biologic Product PlatformMustGrow's plant-based biologics target structural demand for sustainable crop inputs and soil-health solutions. The focused R&D and regulatory pathway plus partnership-led distribution create a differentiated niche, supporting durable competitive positioning if regulatory approvals and field performance continue to validate efficacy.
Modest Leverage / Low DebtA low debt-to-equity ratio limits near-term solvency risk and reduces fixed financial costs, giving management flexibility to prioritize commercialization and R&D. This balance-sheet posture supports the ability to raise incremental capital or invest in scale without heavy near-term interest burdens, aiding multi-month execution.
Bears Say
Very Weak ProfitabilityPersistently low gross margins and deep operating losses indicate the current business mix and pricing lack the unit economics needed for sustainable profitability. Without significant margin expansion or cost reduction, continued losses will erode shareholder equity and limit reinvestment capacity over the medium term.
High Cash BurnNegative operating and free cash flow show the business is consuming cash to fund operations and growth. Ongoing cash burn creates recurring financing needs, increasing dilution or debt risk if internal cash generation doesn't improve, and constrains the firm's ability to invest steadily in commercialization or R&D over coming quarters.
Revenue Base VolatilitySharp year-to-year swings suggest sales are still lumpy and dependent on early contracts or trial programs rather than broad recurring demand. Revenue volatility complicates forecasting, weakens pricing leverage, and raises execution risk for scaling operations and achieving durable margins across multiple seasons.
MustGrow Biologics News
MGRO FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was C$0.49 and its highest was C$0.99 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is C$33.55M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Aug 20, 2026 which is in 88 days.
How were MustGrow Biologics’s earnings last quarter?
Currently, no data Available
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 58,854,360 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in TSE:MGRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp., an agricultural biotech company, focuses om development and commercialization of natural biopesticide, biofumigants, and bioherbicides derived from mustard seed. It provides preplant soil biofumigation, a technology to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and other crops. The company is also developing bioherbicide to treat unwanted plant growth for use in organic agriculture, home, and garden markets, as well as agriculture markets; and postharvest food preservation, an application in sprout, disease, and pathogen treatment for storage and food preservation markets. In addition, it focuses on providing CannaPM, an active ingredient to treat fungal soil diseases, as well as foliar diseases. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.
MGRO Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―
Options Prices
Currently, No data available
---